Analysts’ Viewpoint
Increase in demand for targeted and efficient medical solutions is driving the global liposome drug delivery market. Liposome-based drug delivery systems have a unique advantage, such as encapsulating pharmaceutical agents in lipid bilayers to enhance stability, bioavailability, and precise targeting of diseased cells. Increase in usage in cancer treatment, infectious disease control, and skin care is expected to propel the global liposome drug delivery market demand. Furthermore, surge in demand for targeted drug delivery and streamlined regulatory approval processes are likely to bolster the global liposome drug delivery market development.
Surge in research & development to optimize formulations and overcome production challenges, while balancing innovation and scalability, offers lucrative opportunities to market players. Pharmaceutical companies and biotech firms are collaborating to develop novel liposome drug delivery systems in order to increase market share.
Liposome drug delivery is an innovative approach in the field of medicine, where pharmaceutical agents are encapsulated within tiny lipid bilayer structures known as liposomes.
These lipid-based vesicles offer several advantages in drug delivery compared to traditional methods. These are able to improve the solubility and stability of poorly soluble drugs, enhancing their effectiveness and reducing side effects.
Liposomes also have the potential to target specific cells or tissues, increasing drug concentration at the desired site, and minimizing damage to healthy cells, which is particularly beneficial in treating diseases like cancer.
Versatility of liposomes is evident in their application across various medical domains, including oncology, infectious diseases, dermatology, and more. These can be engineered to carry a wide range of therapeutic agents such as chemotherapy drugs, antibiotics, and anti-inflammatory compounds.
In October 2021, Evonik Health Care introduced LIPEX Flow, an upgraded version of its LIPEX liposome extruder. This enhanced extruder meets the demand for efficient high-pressure extruders for conventional liposomal drug delivery, benefiting applications such as oncology and vaccines.
Rise in demand for precise and efficient drug delivery is driving the global liposome drug delivery market size. This is ascribed to the pressing need for targeted and site-specific therapeutic interventions.
Traditional drug delivery methods often result in the dispersion of medications throughout the body, leading to unintended side effects and diminished treatment efficacy. In this context, liposomes emerge as a revolutionary solution that empowers medical practitioners to achieve unparalleled precision in treating diseases.
Liposomes, spherical lipid-based vesicles, possess a unique ability to encapsulate pharmaceutical compounds within their bilayer structure. This encapsulation not only shields the drugs from degradation, but also facilitates their transport to specific cells or tissues. This capability addresses a longstanding challenge in medicine – how to administer drugs directly to the intended site of action while sparing healthy cells from exposure. By leveraging this inherent characteristic, liposome based drug delivery minimizes off-target effects, reducing the burden of adverse reactions on patients.
The implications of targeted drug delivery through liposomes are far-reaching. Diseases characterized by complex pathophysiology, such as cancer, require treatments that selectively target malignant cells while preserving the surrounding healthy tissue.
Liposomes excel in this regard, enabling oncologists to administer potent chemotherapeutic agents directly to tumor sites. This not only enhances the therapeutic impact, but also alleviates the debilitating side effects associated with systemic chemotherapy.
The precision offered by liposome-mediated drug delivery extends beyond oncology. In infectious diseases, liposomes can be tailored to seek out specific pathogens, improving antimicrobial therapies' effectiveness. Dermatological conditions, too, benefit from liposomal formulations that can be designed to penetrate skin layers precisely, enhancing the delivery of therapeutic agents.
According to a research study by Jingjing Li et al. published in November 2021, researchers developed lyophilized remdesivir liposomes (Rdv-lips). These liposomes can be reconstituted into a liposomal aerosol for pulmonary delivery, enhancing the in vivo behavior of existing remdesivir cyclodextrin compounds (Rdv-cyc). Liposome encapsulation improved solubility and biocompatibility, ultimately enhancing drug efficacy. As companies continue to develop therapeutics against COVID-19, liposome-based drugs and vaccines are poised to play a crucial role.
The global liposome drug delivery market growth can be attributed to a convergence of factors, primarily driven by technological advancements across diverse therapeutic domains and a burgeoning interest in harnessing the potential of liposome-based interventions. This symbiotic relationship between scientific progress and innovative drug delivery strategies has catalyzed a paradigm shift in healthcare.
In the past few years, technological breakthroughs have revolutionized therapeutic approaches across various medical specialties. Fields such as oncology, immunology, and gene therapy have witnessed a surge in novel treatment modalities, capitalizing on cutting-edge research and development. These advancements have paved the way for the integration of liposome drug delivery systems, capitalizing on their unique attributes to enhance treatment outcomes.
Liposomes, with their capacity for encapsulating a wide array of pharmaceutical agents, have seamlessly integrated into these therapeutic areas. In oncology, for instance, the advent of targeted therapies and precision medicine has synergized remarkably well with liposomal technology.
Liposomes can encapsulate potent chemotherapy drugs, shielding healthy tissues from their toxic effects and allowing for concentrated delivery directly to tumor sites. This approach not only bolsters therapeutic efficacy, but also mitigates the distressing side effects associated with conventional treatments.
In the realm of gene therapy, where the manipulation of genetic material holds immense promise for treating genetic disorders, liposome-based carriers offer a safe and efficient means of delivering therapeutic genes into cells. The lipid bilayers of liposomes provide a protective envelope for fragile gene payloads, facilitating their successful transfer and integration into target cells.
The growing interest in liposome drug delivery is evidenced by collaborations between pharmaceutical giants and innovative biotech firms. These partnerships are catalyzing the development of increasingly sophisticated liposomal formulations tailored for specific therapeutic objectives. Such collaborations are not only expanding the liposome drug delivery market, but also fostering a dynamic ecosystem of research and innovation.
In terms of liposome structure, the unilamellar liposomes segment accounted for the largest global liposome drug delivery market share in 2022. These single-layer lipid vesicles play a pivotal role in revolutionizing drug administration by encapsulating pharmaceutical agents with precision.
Unilamellar liposomes offer enhanced drug stability, controlled release, and targeted delivery to specific cells or tissues. Their versatility spans various therapeutic domains, making them a preferred choice in oncology, infectious diseases, and beyond. As the market continues to expand, unilamellar liposomes remain a cornerstone of advanced drug delivery strategies, underlining their significance in improving treatment efficacy and patient well-being.
Based on product, the liposomal doxorubicin segment dominated the global liposome drug delivery market in 2022. Liposomal doxorubicin, a prominent segment in the pharmaceutical landscape, holds a dominant position in advanced cancer therapies.
This encapsulated formulation of the potent chemotherapy drug doxorubicin demonstrates exceptional efficacy in oncology, particularly in treating solid tumors such as breast and ovarian cancers.
By utilizing liposomes, it delivers doxorubicin directly to cancer cells while minimizing damage to healthy tissues, mitigating adverse effects. This targeted approach enhances treatment outcomes, reduces side effects, and exemplifies the strides made in personalized and precision medicine, positioning liposomal doxorubicin as a cornerstone in modern cancer treatment strategies.
In terms of technology, the stealth liposome technology segment accounted for significant share of the global liposome drug delivery market in 2022. Stealth liposome technology is reshaping pharmaceutical innovation. By incorporating polyethylene glycol (PEG) coatings, stealth liposomes excel in evading immune detection, extending circulation, and enhancing drug targeting. This innovation finds its prominence in oncology, optimizing drug delivery to cancerous cells while minimizing side effects.
With its versatile potential to encapsulate diverse therapeutics and improve bioavailability, stealth liposome technology drives advancements in personalized medicine and reinforces the market's trajectory toward more efficient, targeted, and patient-centric treatments.
Based on application, the cancer therapy segment dominated the global market in 2022. Liposomes offer remarkable precision by directly targeting cancer cells while sparing healthy tissue, reducing side effects.
Liposomal formulations enhance drug bioavailability and enable controlled release, optimizing treatment outcomes. With ongoing research and development, liposome-based cancer therapies continue to expand their applications, driving market growth.
As personalized medicine gains traction, the synergy between liposome drug delivery and cancer therapy positions this segment at the forefront of innovative healthcare solutions. For instance, Foad Rammasi and Neda Esfandiari's May 2021 research emphasized liposomes' flexibility and chemical modification potential in cancer therapeutics. Conjugating polymers, ligands, and molecules enhances liposomes' pharmacological benefits, boosting anticancer treatment efficacy.
As per liposome drug delivery market trends, North America dominated the global industry in 2022. The region's supremacy is underpinned by a confluence of factors, including robust research & development initiatives, well-established healthcare infrastructure, and a receptive regulatory environment.
Presence of leading pharmaceutical companies, academic institutions, and research centers further fuels advancements in liposome technology. North America's dominance is particularly evident in its extensive utilization of liposome-based drug delivery systems across various therapeutic domains, ranging from oncology to infectious diseases.
North America's focus on precision medicine and personalized treatment approaches aligns seamlessly with the capabilities of liposomes, which enable targeted and efficient drug delivery, thereby enhancing therapeutic outcomes. Moreover, strategic collaborations between academia, industry, and research institutions in the region play a pivotal role in fostering innovation and accelerating the adoption of liposome drug delivery.
According to liposome drug delivery market analysis, the industry in Asia Pacific is experiencing rapid and robust growth. This momentum can be attributed to a convergence of factors that create a fertile ground for innovation and adoption. The region's burgeoning healthcare infrastructure, combined with increasing investments in research & development, has catalyzed the development and uptake of liposome-based drug delivery systems. The region's diverse and large patient population presents a significant market for novel treatment approaches that enhance therapeutic efficacy while minimizing side effects.
Leading players in the market are engaged in merger & acquisition, strategic partnerships, and new product launches to expand industry presence.
Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Inc., CELSION Corporation, Abbott, Ipsen Pharma, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited are the prominent players in the market.
Each of the prominent players has been profiled in the liposome drug delivery market research report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
| Attribute | Detail |
|---|---|
|
Size in 2022 |
US$ 4.7 Bn |
|
Forecast (Value) in 2031 |
More than US$ 10.0 Bn |
|
Growth Rate (CAGR) |
8.5% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 4.7 Bn in 2022.
It is projected to reach more than US$ 10.0 Bn by 2031.
It is anticipated to grow at a CAGR of 8.5% from 2023 to 2031.
Focus on reducing side effects & improving drug bioavailability, higher targeted drug delivery demand, and technological advancements in various therapeutic areas.
The liposomal doxorubicin product segment accounted for more than 40.0% share in 2022.
North America is expected to be highly lucrative region from 2023 to 2031.
Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Inc., CELSION Corporation, Abbott, Ipsen Pharma, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Liposome Drug Delivery Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Liposome Drug Delivery Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Overview: Liposome Drug delivery Systems
5.3. Regulatory Scenario
5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Liposome Drug Delivery Market Analysis and Forecast, by Liposome Structure
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Liposome Structure, 2017-2031
6.3.1. Unilamellar Liposomes
6.3.1.1. Small
6.3.1.2. Large
6.3.2. Multilamellar liposomes
6.3.3. Others
6.4. Market Attractiveness Analysis, by Liposome Structure
7. Global Liposome Drug Delivery Market Analysis and Forecast, by Product
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Product, 2017-2031
7.3.1. Liposomal Doxorubicin
7.3.2. Liposomal Paclitaxel
7.3.3. Liposomal Amphotericin B
7.3.4. Others
7.4. Market Attractiveness Analysis, by Product
8. Global Liposome Drug Delivery Market Analysis and Forecast, by Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Technology, 2017-2031
8.3.1. Stealth Liposome Technology
8.3.2. Non PEGylated Liposome Technology
8.3.3. DepoFoam Liposome Technology
8.3.4. Lysolipid Thermally Sensitive Liposome Technology
8.4. Market Attractiveness Analysis, by Technology
9. Global Liposome Drug Delivery Market Analysis and Forecast, by Application
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Application, 2017-2031
9.3.1. Fungal Diseases
9.3.2. Cancer Therapy
9.3.3. Pain Management
9.3.4. Viral Vaccines
9.3.5. Photodynamic Therapy
9.3.6. Others
9.4. Market Attractiveness Analysis, by Application
10. Global Liposome Drug Delivery Market Analysis and Forecast, by End-user
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by End-user, 2017-2031
10.3.1. Hospitals
10.3.2. Specialty Centers
10.3.3. Ambulatory Surgical Centers
10.3.4. Others
10.4. Market Attractiveness Analysis, by End-user
11. Global Liposome Drug Delivery Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Liposome Drug Delivery Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Liposome Structure, 2017-2031
12.2.1. Unilamellar Liposomes
12.2.1.1. Small
12.2.1.2. Large
12.2.2. Multilamellar liposomes
12.2.3. Others
12.3. Market Value Forecast, by Product, 2017-2031
12.3.1. Liposomal Doxorubicin
12.3.2. Liposomal Paclitaxel
12.3.3. Liposomal Amphotericin B
12.3.4. Others
12.4. Market Value Forecast, by Technology, 2017-2031
12.4.1. Stealth Liposome Technology
12.4.2. Non PEGylated Liposome Technology
12.4.3. DepoFoam Liposome Technology
12.4.4. Lysolipid Thermally Sensitive Liposome Technology
12.5. Market Value Forecast, by Application, 2017-2031
12.5.1. Fungal Diseases
12.5.2. Cancer Therapy
12.5.3. Pain Management
12.5.4. Viral Vaccines
12.5.5. Photodynamic Therapy
12.5.6. Others
12.6. Market Value Forecast, by End-user, 2017-2031
12.6.1. Hospitals
12.6.2. Specialty Centers
12.6.3. Ambulatory Surgical Centers
12.6.4. Others
12.7. Market Value Forecast, by Country, 2017-2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Liposome Structure
12.8.2. By Product
12.8.3. By Technology
12.8.4. By Application
12.8.5. By End-user
12.8.6. By Country
13. Europe Liposome Drug Delivery Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Liposome Structure, 2017-2031
13.2.1. Unilamellar Liposomes
13.2.1.1. Small
13.2.1.2. Large
13.2.2. Multilamellar liposomes
13.2.3. Others
13.3. Market Value Forecast, by Product, 2017-2031
13.3.1. Liposomal Doxorubicin
13.3.2. Liposomal Paclitaxel
13.3.3. Liposomal Amphotericin B
13.3.4. Others
13.4. Market Value Forecast, by Technology, 2017-2031
13.4.1. Stealth Liposome Technology
13.4.2. Non PEGylated Liposome Technology
13.4.3. DepoFoam Liposome Technology
13.4.4. Lysolipid Thermally Sensitive Liposome Technology
13.5. Market Value Forecast, by Application, 2017-2031
13.5.1. Fungal Diseases
13.5.2. Cancer Therapy
13.5.3. Pain Management
13.5.4. Viral Vaccines
13.5.5. Photodynamic Therapy
13.5.6. Others
13.6. Market Value Forecast, by End-user, 2017-2031
13.6.1. Hospitals
13.6.2. Specialty Centers
13.6.3. Ambulatory Surgical Centers
13.6.4. Others
13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
13.7.1. Germany
13.7.2. U.K
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Liposome Structure
13.8.2. By Product
13.8.3. By Technology
13.8.4. By Application
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Liposome Drug Delivery Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Liposome Structure, 2017-2031
14.2.1. Unilamellar Liposomes
14.2.1.1. Small
14.2.1.2. Large
14.2.2. Multilamellar liposomes
14.2.3. Others
14.3. Market Value Forecast, by Product, 2017-2031
14.3.1. Liposomal Doxorubicin
14.3.2. Liposomal Paclitaxel
14.3.3. Liposomal Amphotericin B
14.3.4. Others
14.4. Market Value Forecast, by Technology, 2017-2031
14.4.1. Stealth Liposome Technology
14.4.2. Non PEGylated Liposome Technology
14.4.3. DepoFoam Liposome Technology
14.4.4. Lysolipid Thermally Sensitive Liposome Technology
14.5. Market Value Forecast, by Application, 2017-2031
14.5.1. Fungal Diseases
14.5.2. Cancer Therapy
14.5.3. Pain Management
14.5.4. Viral Vaccines
14.5.5. Photodynamic Therapy
14.5.6. Others
14.6. Market Value Forecast, by End-user, 2017-2031
14.6.1. Hospitals
14.6.2. Specialty Centers
14.6.3. Ambulatory Surgical Centers
14.6.4. Others
14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Liposome Structure
14.8.2. By Product
14.8.3. By Technology
14.8.4. By Application
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Liposome Drug Delivery Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Liposome Structure, 2017-2031
15.2.1. Unilamellar Liposomes
15.2.1.1. Small
15.2.1.2. Large
15.2.2. Multilamellar liposomes
15.2.3. Others
15.3. Market Value Forecast, by Product, 2017-2031
15.3.1. Liposomal Doxorubicin
15.3.2. Liposomal Paclitaxel
15.3.3. Liposomal Amphotericin B
15.3.4. Others
15.4. Market Value Forecast, by Technology, 2017-2031
15.4.1. Stealth Liposome Technology
15.4.2. Non PEGylated Liposome Technology
15.4.3. DepoFoam Liposome Technology
15.4.4. Lysolipid Thermally Sensitive Liposome Technology
15.5. Market Value Forecast, by Application, 2017-2031
15.5.1. Fungal Diseases
15.5.2. Cancer Therapy
15.5.3. Pain Management
15.5.4. Viral Vaccines
15.5.5. Photodynamic Therapy
15.5.6. Others
15.6. Market Value Forecast, by End-user, 2017-2031
15.6.1. Hospitals
15.6.2. Specialty Centers
15.6.3. Ambulatory Surgical Centers
15.6.4. Others
15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Liposome Structure
15.8.2. By Product
15.8.3. By Technology
15.8.4. By Application
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Liposome Drug Delivery Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Liposome Structure, 2017-2031
16.2.1. Unilamellar Liposomes
16.2.1.1. Small
16.2.1.2. Large
16.2.2. Multilamellar liposomes
16.2.3. Others
16.3. Market Value Forecast, by Product, 2017-2031
16.3.1. Liposomal Doxorubicin
16.3.2. Liposomal Paclitaxel
16.3.3. Liposomal Amphotericin B
16.3.4. Others
16.4. Market Value Forecast, by Technology, 2017-2031
16.4.1. Stealth Liposome Technology
16.4.2. Non PEGylated Liposome Technology
16.4.3. DepoFoam Liposome Technology
16.4.4. Lysolipid Thermally Sensitive Liposome Technology
16.5. Market Value Forecast, by Application, 2017-2031
16.5.1. Fungal Diseases
16.5.2. Cancer Therapy
16.5.3. Pain Management
16.5.4. Viral Vaccines
16.5.5. Photodynamic Therapy
16.5.6. Others
16.6. Market Value Forecast, by End-user, 2017-2031
16.6.1. Hospitals
16.6.2. Specialty Centers
16.6.3. Ambulatory Surgical Centers
16.6.4. Others
16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & South Africa
16.8. Market Attractiveness Analysis
16.8.1. By Liposome Structure
16.8.2. By Product
16.8.3. By Technology
16.8.4. By Application
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix, by tier and size of companies
17.2. Market Share Analysis, by Company, 2021
17.3. Company Profiles
17.3.1. Johnson & Johnson Services, Inc.
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. Gilead Sciences, Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Sun Pharmaceutical Industries Ltd.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Novartis AG
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Teva Pharmaceutical Industries Ltd
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Janssen Pharmaceuticals, Inc.
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. CELSION Corporation
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Abbott
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Ipsen Pharma
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Spectrum Pharmaceuticals, Inc.
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview
17.3.11. Takeda Pharmaceutical Company Limited
17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.11.2. Product Portfolio
17.3.11.3. Financial Overview
17.3.11.4. SWOT Analysis
17.3.11.5. Strategic Overview
List of Tables
Table 01: Pipeline Analysis - Liposome Drug Delivery Systems
Table 02: Clinically Marketed Liposome Drugs
Table 03: Regulations - Principle difference between U.S., EU and India
Table 04: Regulatory Scenario Assessment - Administrative Requirements
Table 05: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027
Table 06: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027
Table 07: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027
Table 08: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Region, 2017-2027
Table 09: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country, 2017-2027
Table 10: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027
Table 11: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027
Table 12: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027
Table 13: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
Table 14: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027
Table 15: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027
Table 16: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027
Table 17: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
Table 18: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027
Table 19: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027
Table 20: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027
Table 21: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
Table 22: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027
Table 23: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027
Table 24: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027
Table 25: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
Table 26: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027
Table 27: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027
Table 28: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027
List of Figures
Figure 01: Global Liposome Drug Delivery Market Snapshot
Figure 02: Global Liposome Drug Delivery Market Value (US$ Mn), by Region, 2022 and 2031
Figure 03: Therapeutic applications of liposomes in drug delivery
Figure 04: Advantages of liposome drug delivery system
Figure 05: Global Liposome Drug Delivery Market Value (US$ Mn) and Y-o-Y (%) Forecast, 2017-2027
Figure 06: Global Liposome Drug Delivery Market Value Share, by Product, 2022
Figure 07: Global Liposome Drug Delivery Market Value Share, by Technology, 2022
Figure 08: Global Liposome Drug Delivery Market Value Share, by Application, 2022
Figure 09: Global Liposome Drug Delivery Market Value Share, by Region, 2022
Figure 10: Regulatory Approval Process - U.S.
Figure 11: Regulatory Approval Process - Europe
Figure 12: Regulatory Approval Process - India
Figure 13: Global Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031
Figure 14: Global Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031
Figure 15: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Doxorubicin, 2017-2027
Figure 16: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Paclitaxel, 2017-2027
Figure 17: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Amphotericin B, 2017-2027
Figure 18: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
Figure 19: Global Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031
Figure 20: Global Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031
Figure 21: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Stealth Liposome Technology, 2017-2027
Figure 22: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Non-PEGylated Liposome Technology, 2017-2027
Figure 23: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by DepoFoam Liposome Technology, 2017-2027
Figure 24: Global Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031
Figure 25: Global Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031
Figure 26: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Fungal Diseases, 2017-2027
Figure 27: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pain Management, 2017-2027
Figure 28: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cancer Therapy, 2017-2027
Figure 29: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Viral Vaccines, 2017-2027
Figure 30: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Photodynamic therapy, 2017-2027
Figure 31: Global Liposome Drug Delivery Market - Regional Outlook
Figure 32: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, 2017-2027
Figure 33: Global Liposome Drug Delivery Market Value Share Analysis, by Region, 2022 and 2031
Figure 34: Global Liposome Drug Delivery Market Attractiveness Analysis, by Region, 2017-2031
Figure 35: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
Figure 36: North America Liposome Drug Delivery Market Value Share Analysis, by Country, 2022 and 2031
Figure 37: North America Liposome Drug Delivery Market Attractiveness Analysis, by Country, 2017-2031
Figure 38: North America Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031
Figure 39: North America Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031
Figure 40: North America Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031
Figure 41: North America Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031
Figure 42: North America Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031
Figure 43: North America Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031
Figure 44: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
Figure 45: Europe Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 46: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 47: Europe Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031
Figure 48: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031
Figure 49: Europe Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031
Figure 50: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031
Figure 51: Europe Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031
Figure 52: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031
Figure 53: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
Figure 54: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 55: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 56: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031
Figure 57: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031
Figure 58: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031
Figure 59: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031
Figure 60: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031
Figure 61: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031
Figure 62: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
Figure 63: Latin America Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 64: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 65: Latin America Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031
Figure 66: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031
Figure 67: Latin America Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031
Figure 68: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031
Figure 69: Latin America Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031
Figure 70: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031
Figure 71: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
Figure 72: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 73: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 74: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031
Figure 75: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031
Figure 76: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031
Figure 77: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031
Figure 78: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031
Figure 79: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Liposome Drug Delivery Market
